奥美沙坦对高血压患者血压晨峰及尿微量白蛋白的影响

Effect of olmesartan on morning blood pressure surge and microalbuminuria in hypertensive patients

目的观察奥美沙坦对原发性高血压患者血压晨峰及尿微量白蛋白的变化。方法选择63例存在血压晨峰的高血压患者,随机分为对照组31例、治疗组32例。对照组患者给予吲达帕胺缓释片1.5 mg/d,治疗组给予奥美沙坦片20mg/d。两组患者均在服药8周后再次行24 h动态血压监测,并记录昼间、夜间及晨起血压,并测量两组患者治疗前后尿微量白蛋白的变化。结果与对照组治疗后比较,治疗组连续治疗8周后血压晨峰明显降低[(17.9±3.6)mm Hg vs.(36.9±4.1)mm Hg,P<0.05],治疗组尿微量白蛋白明显降低[(26.6±9.3)mg/L vs.(54.9±10.5)mg/L,P<0.05]。结论奥美沙坦可以有效控制原发性高血压患者的血压晨峰,并有效降低尿微量白蛋白,减少早期肾损害的发生。

Objective To study the effect of olmesartan on morning blood pressure surge（MBPS） and microalbuminuria（m ALB） in hypertensive patients. Methods Sixty-three primary hypertensive patients with MBPS were randomly divided into treatment group and control group; treatment group were givenolmesartan 20 mg orally once a day,and control group were given indapamide 1.5 mg orally once a day for 8 weeks. 24 h ambulatory blood pressure,day,night and morning blood pressure, and m ALB level were determined before and after treatment. Results After 8 weeks of continuous treatment,the MBPS were significantly lower in treatment group than control group [（17.9 ±3.6）mm Hg vs.（36.9 ±4.1）mm Hg,P 0.05 ]; them ALBlevel were significantly lower in treatment group than control group [（26.6 ±9.3）mg / L vs.（54.9±10.5） mg / L,P 〈0.05]. Conclusion Olmesartan can effectively alleviate renal damage in primary hypertensive patients by controlling MBPS and reducing the m ALB level.